PORT HUENEME, CA--(Marketwired - Jan 26, 2016) - Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (NASDAQ: SBOT) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (“KLH”), presented scientific research on nanofiltration development at last week’s PepTalk: The Protein Science Week Conference, in San Diego, California, Jan 18-22, 2016.
The research poster presentation, titled “Development of a 20N Virus Filtration Process for Keyhole Limpet Hemocyanin (KLH) - A High Molecular Weight Protein,” was authored by Stellar scientists Catherine Brisson, Ph.D., Laura Milbrandt, Zully Aguilar, and William Bailey. The presentation reported data from the Company’s development and validation of filtration methods for the removal of viruses during manufacturing processes of KLH products.
KLH is often used as a carrier molecule and active ingredient in immunotherapies or as an injectable to assess immune effects of new drugs in clinical settings. The rising use of KLH in the clinical development of new immunotherapies highlights the need for appropriate purification methods including the implementation of a robust viral clearance step into the production process. However, due to the large size and complexity of the KLH molecule, development and optimization of viral clearance can be a challenge. At PepTalk, the Company presented results from its development of a nanofiltration method that demonstrated effective removal of the viruses evaluated in the study, and met suggested regulatory criteria for robustness.
Find Stellar’s poster presentation here: http://bit.ly/1nu9vrK
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer’s and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.